1. Home
  2. OTLK vs QRHC Comparison

OTLK vs QRHC Comparison

Compare OTLK & QRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OTLK
  • QRHC
  • Stock Information
  • Founded
  • OTLK 2010
  • QRHC N/A
  • Country
  • OTLK United States
  • QRHC United States
  • Employees
  • OTLK N/A
  • QRHC N/A
  • Industry
  • OTLK Biotechnology: Biological Products (No Diagnostic Substances)
  • QRHC Environmental Services
  • Sector
  • OTLK Health Care
  • QRHC Utilities
  • Exchange
  • OTLK Nasdaq
  • QRHC Nasdaq
  • Market Cap
  • OTLK 48.3M
  • QRHC 41.8M
  • IPO Year
  • OTLK 2016
  • QRHC N/A
  • Fundamental
  • Price
  • OTLK $1.09
  • QRHC $1.64
  • Analyst Decision
  • OTLK Buy
  • QRHC Buy
  • Analyst Count
  • OTLK 5
  • QRHC 1
  • Target Price
  • OTLK $8.50
  • QRHC $12.50
  • AVG Volume (30 Days)
  • OTLK 8.2M
  • QRHC 53.5K
  • Earning Date
  • OTLK 08-14-2025
  • QRHC 11-06-2025
  • Dividend Yield
  • OTLK N/A
  • QRHC N/A
  • EPS Growth
  • OTLK N/A
  • QRHC N/A
  • EPS
  • OTLK N/A
  • QRHC N/A
  • Revenue
  • OTLK $1,505,322.00
  • QRHC $270,706,000.00
  • Revenue This Year
  • OTLK N/A
  • QRHC N/A
  • Revenue Next Year
  • OTLK $484.88
  • QRHC $4.24
  • P/E Ratio
  • OTLK N/A
  • QRHC N/A
  • Revenue Growth
  • OTLK N/A
  • QRHC N/A
  • 52 Week Low
  • OTLK $0.79
  • QRHC $1.41
  • 52 Week High
  • OTLK $7.26
  • QRHC $9.14
  • Technical
  • Relative Strength Index (RSI)
  • OTLK 37.49
  • QRHC 40.00
  • Support Level
  • OTLK $1.02
  • QRHC $1.59
  • Resistance Level
  • OTLK $1.19
  • QRHC $1.78
  • Average True Range (ATR)
  • OTLK 0.22
  • QRHC 0.11
  • MACD
  • OTLK -0.04
  • QRHC -0.00
  • Stochastic Oscillator
  • OTLK 11.18
  • QRHC 20.00

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

About QRHC Quest Resource Holding Corporation

Quest Resource Holding Corp is a national provider of waste and recycling services to customers from across multiple industry sectors that are typically larger, multi-location businesses. The company creates customer-specific programs and perform the related services for the collection, processing, recycling, disposal, and tracking of waste streams and recyclables. The company's services focus on the waste streams and recyclables from box, grocers, and other specialty retailers; automotive after-market operations such as automotive maintenance, quick lube, dealerships, and collision repair; transportation, logistics, and fleet operators; manufacturing and industrial facilities; multi-family and commercial properties; restaurant chains and food operations, etc.

Share on Social Networks: